The Military HIV Research Program ( MHRP ) Clinical Trial Unit
$42,798UM1FY2022AINIH
Henry M. Jackson Fdn For The Adv Mil/Med, Rockville MD
Investigators
Linked publications & trials
Paper 38761816Paper 38570632Paper 38168661Paper 37616058Paper 37368929Paper 37287871Paper 37201761Paper 36856116Paper 36804957Paper 36780493Paper 35483735Paper 34693933Paper 34398958Paper 34322136Paper 33730454Paper 33316345Paper 32442195Paper 32265361Paper 32145827Paper 32015557Paper 31900486Paper 31528850Paper 31487271Paper 31371262Paper 30865794Paper 29770360Paper 29406428Paper 29365083Paper 28742529Paper 27677161Paper 27240787Paper 27025337Paper 24938526Paper 24562349Paper 24445367Paper 23924996
Abstract
Abstract COVID-19 Vaccine Clinical Development Team The USG enterprise to develop and optimize vaccine prevention modalities for SARS CoV-2 incorporates the DAIDS HVTN as a key partner in strategic development, research prioritization and execution, landscape analysis for future directions and analysis of outcomes. Dr. Robb has co-chaired and participated in the USG Vaccine Development Team for clinical research along with the PI and others within the HVTN. The administrative amendment to CTU funding to HJF will sustain Dr. Robbâs role in this capacity.
View original record on NIH RePORTER →